Valeant to acquire Swiss Generics Firm | February 7, 2011 Issue - Vol. 89 Issue 6 | Chemical & Engineering News
Volume 89 Issue 6 | p. 16 | Concentrates
Issue Date: February 7, 2011

Valeant to acquire Swiss Generics Firm

Department: Business
Keywords: divestment, esters, aromas, specialty chemicals

In a bid to strengthen its position in Central and Eastern Europe, Valeant Pharmaceuticals (formerly Biovail) will pay $480 million for privately owned over-the-counter and generic drug firm PharmaSwiss. Last year, PharmaSwiss posted about $250 million in sales, a level that has been growing roughly 20% annually. Biovail took the Valeant name last fall after its $3.3 billion acquisition of that firm.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment